C
Corneagen
Innovative corneal therapeutics and tissue services advancing ocular surgery and patient care
About Corneagen
CorneaGen is a pioneering company in the field of corneal therapeutics and tissue services, dedicated to transforming cornea care through innovative and affordable solutions. The company serves ophthalmologists, surgeons, and healthcare providers, primarily focusing on the ocular surgery market. CorneaGen operates on a business-to-business (B2B) model, providing high-quality corneal tissue, surgical devices, and advanced therapeutic solutions. Revenue is generated through the sale of corneal tissue for transplantation, surgical instruments, and related medical products. The company also invests in research and development to continuously advance corneal care technologies. CorneaGen's commitment to innovation and education is evident through its extensive range of educational videos, webinars, and wet labs designed to support the professional development of eye care specialists. The company also offers reimbursement assistance and adverse reaction reporting to ensure comprehensive support for its clients. Key products include VisionGraft, EndoSerter, and various pre-loaded glass cannulas. CorneaGen's strategic partnerships and collaborations further enhance its ability to deliver cutting-edge solutions to the market.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2016
- Headquarters
- Seattle, United States
- Employees
- 182
- Open positions
- 7
- Dealroom signal
- 81.8/100
- Industry
- Health
- Sub-industry
- BioTechnology, Medical Devices
- Sector
- Biotech & Life Sciences, Innovation Management, Biotechnology, Health Diagnostics, Biotech and Pharma, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- B2B, B2C
News
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES BOther financing | Oct 2019 | $37M | $148M | Flying L Partners | ↗ |
| DEBTDebt | Oct 2019 | $25M | — | Petrichor | — |
Growth signals
Latest recorded traffic for Corneagen is 6.3K monthly website visits, up 14.5% over the last three months. Corneagen's team grew 19.7% over the past year.
Open positions
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Corneagen in the Seattle ecosystem
The Corneagen office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A1 investor entered at this stage
Flying L Partners
Series B and later1 investor entered at this stage
- PEPetrichor
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Corneagen on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Corneagen’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.










